Welcome, this website is intended for all international healthcare professionals in uro-oncology. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor–Targeted Therapy

Take Home Message

The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor–targeted therapy. New data have recently become available showing a survival benefit for cabozantinib.

Keywords: Nivolumab, Cabozantinib, Renal cancer, Guidelines, European Association of Urology.


a The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK

b Department of Urology, Ludwig-Maximilians University, Munich, Germany

c Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden

d Department of Urology, University of Rennes, Rennes, France

e Division of Urology, University of Texas Medical School at Houston, Houston, TX, USA

f Department of Urology, Skåne University Hospital, Malmö, Sweden

g Patient Advocate International Kidney Cancer Coalition (IKCC), University Medical Centre Utrecht, Nephrology Department, Utrecht, The Netherlands

h Department of Urology, Sunderby Hospital, Sunderby, Sweden

i Department of Urology, Faculty Hospital and Faculty of Medicine in Pilsen, Charles University in Prague, Prague, Czech Republic

j Department of Urology and Urologic Oncology, Hannover Medical School, Hannover, Germany

k Academic Urology Unit, University of Aberdeen, Aberdeen, UK

l Department of Urology, Coimbra University Hospital, Coimbra, Portugal

m Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany

n Division of Urology, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy

o Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

Corresponding author. The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London EC1A7BE, UK. Tel. +44 793 204 81 09; Fax: +44 207 601 85 22.